Clinical Trials on Morquio B Disease

Total 378393 results

Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma

Marginal Zone B-cell Lymphoma

Italy, France
George Washington University

Withdrawn

Diet, Physical Activity and Body Composition Changes During R-CHOP (R-CHOP-OS)

Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | DLBCL

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Mundipharma-EDO GmbH

Withdrawn

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

United Kingdom
Zhengzhou University

Completed

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma | Relapsed and Refractory

China
International Extranodal Lymphoma Study Group (IELSG)

Terminated

This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas (IELSG33)

Diffuse Large B-Cell Lymphoma of the Breast
Korea Cancer Center Hospital

Unknown

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

Relapsed or Refractory Marginal Zone B-cell Lymphoma

Korea, Republic of
Kite, A Gilead Company

Completed

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)

Relapsed Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL)

United States, Netherlands, Canada, France, Germany, Israel
National Cancer Institute (NCI)

Completed

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Burkitt Lymphoma | High-grade B-cell Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | T-cell/Histocyte-rich Large B-cell Lymphoma | Germinal Center B-cell Type (GCB)

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Study of E7777 Prior to Kymriah for R/R DLBCL

Diffuse Large B Cell Lymphoma | DLBCL | High-grade B-cell Lymphoma | DLBCL Arising From Follicular Lymphoma

United States
National Taiwan University Hospital

Not yet recruiting

Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma (LCMALT)

Antibiotics-unresponsive MALT Lymphoma | Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma | Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT)

Taiwan
Czech Lymphoma Study Group
Hoffmann-La Roche; Ministry of Health, Czech Republic

Completed

R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas (R-MCEB)

Diffuse Large B-Cell Lymphoma. | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma Grade III

Czech Republic
Genmab
AbbVie

Terminated

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma

United States, Spain, Netherlands, Belgium, France, Denmark
Jennifer Crombie, MD
Merck Sharp & Dohme LLC

Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma Refractory | Primary Mediastinal Large B-Cell Lymphoma Recurrent | Epstein-Barr Virus Positive Diffuse Large...

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
Shanghai YingLi Pharmaceutical Co. Ltd.

Unknown

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

B-cell Chronic Lymphocytic Leukemia | B-cell Lymphoma Recurrent

China
Emory University
Celgene Corporation

Terminated

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

B-Cell Lymphoma | Hodgkin's Disease

United States
California Pacific Medical Center Research Institute
University of California, San Francisco

Active, not recruiting

The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO). (BeNEG-DO)

Chronic Hepatitis B Virus

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL (SPINOZA)

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive

United States
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Recruiting

Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects (XT1061)

Chronic Hepatitis b

China
Chinese University of Hong Kong

Recruiting

Prospective Evaluation of a Fast-track Treatment Pathway for Patients With Chronic Hepatitis B Under Primary Care

Chronic Hep B

Hong Kong
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI); AbbVie

Withdrawn

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Richter Syndrome | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
Exelixis

Terminated

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Non-Hodgkin's Lymphoma (NHL) | Mantle Cell Lymphoma (MCL) | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)

United States
Pell Bio-Med Technology Co., Ltd.

Recruiting

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
The Lymphoma Academic Research Organisation
Roche Pharma AG

Terminated

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (VISMOLY)

Chronic Lymphocytic Leukemia | Primary Central Nervous System Lymphoma | Diffuse Large B-cell Lymphoma | Indolent Non-hodgkin Lymphoma

France
Chongqing University Cancer Hospital

Recruiting

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

China
The Affiliated Hospital of Qingdao University

Not yet recruiting

Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL

Diffuse Large B Cell Lymphoma
Antengene Corporation

Recruiting

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL (SWATCH)

Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin Lymphoma

China
Peking Union Medical College Hospital

Recruiting

Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL (NHL-011)

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-cell

China
Centre Hospitalier Universitaire, Amiens
Institut Bergonié; Centre Henri Becquerel; Saint-Louis Hospital, Paris, France; Henri Mondor University Hospital and other collaborators

Recruiting

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (Relyage)

Chemotherapy | Elderly | Diffuse Large B-Cell Lymphoma (DLBCL), Nos

France
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Japan
Karyopharm Therapeutics Inc

Suspended

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma

United States
Second Affiliated Hospital of Soochow University

Enrolling by invitation

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Diffuse Large B-cell Lymphoma

China
Bristol-Myers Squibb

Completed

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Lymphoma. Non-Hodgkin

Germany, Italy, United States, Spain, Netherlands, Australia, United Kingdom, Belgium, France, Canada, Sweden, Singapore
Carevive Systems, Inc.

Completed

Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL

Follicular Lymphoma | Diffuse Large B Cell Lymphoma

United States
The Lymphoma Academic Research Organisation

Completed

Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years

Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma

Belgium, France
Korea Cancer Center Hospital

Unknown

A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Relapsed or Refractory Diffuse Large B Cell Lymphoma

Korea, Republic of
Celgene Corporation

Terminated

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

United States, Canada, Australia
Wake Forest University Health Sciences

Withdrawn

Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

B-cell Malignancy

China
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

B-cell Malignancy

China
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Indolent Non Follicular Lymphomas Prognostic Project

Indolent B-Cell Lymphomas

France, Italy, Brazil, Austria, Portugal, Ukraine
Masonic Cancer Center, University of Minnesota

Completed

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Refractory B-Lineage Leukemia | Relapsed B-Lineage Leukemia | Refractory B-Lineage Lymphoma | Relapsed B-Lineage Lymphoma

United States
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
M.D. Anderson Cancer Center

Withdrawn

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

B-cell Lymphoma | Large B-cell Lymphoma

United States
Brian Hill
The Cleveland Clinic

Terminated

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Lymphoma | B Cell Lymphoma

United States

Clinical Trials on Morquio B Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations